Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Corvus Pharmaceuticals, Inc. (CRVS : NSDQ)

• Company Description    Corvus Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of immuno-oncology therapies to harness the immune system to attack cancer cells. Its products include CPI-444, Adenosine production inhibitor, Adenosine A2B antagonist and Interleukin-2 (IL-2)-inducible T cell kinase (ITK) inhibitors. Corvus Pharmaceuticals, Inc. is based in Burlingame, California. Number of Employees: 31

• Price / Volume Information    Yesterday's Closing Price: $5.83 Daily Weekly Monthly 20 Day Moving Average: 575,829 shares Shares Outstanding: 74.51 (millions) Market Capitalization: $434.42 (millions) Beta: 0.52 52 Week High: $10.00 52 Week Low: $2.54 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 20.21% 18.09% 12 Week 48.35% 34.75% Year To Date 8.97% 1.13%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 901 Gateway Boulevard Third Floor - South San Francisco,CA 94080 USA ph: 650-900-4520 fax: - llea@corvuspharma.com http://www.corvuspharma.com

• General Corporate Information    Officers Richard A. Miller - President; Chief Executive Officer and Director Leiv Lea - Chief Financial Officer Ian T. Clark - Director Linda S. Grais - Director Scott W. Morrison - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 221015100 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/11/25 Share - Related Items Shares Outstanding: 74.51 Most Recent Split Date: (:1) Beta: 0.52 Market Capitalization: $434.42 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.13 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.51 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/11/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 4.95 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -42.86% vs. Previous Quarter: 23.08% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - -28.61 03/31/25 - -24.04 12/31/24 - -90.91 ROA 06/30/25 - -18.05 03/31/25 - -13.90 12/31/24 - -50.69 Current Ratio 06/30/25 - 8.91 03/31/25 - 4.90 12/31/24 - 1.54 Quick Ratio 06/30/25 - 8.91 03/31/25 - 4.90 12/31/24 - 1.54 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - 1.18 03/31/25 - 0.72 12/31/24 - 0.51 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©